Do GLP-1 drugs lower blood cancer risk? What 405,000 patients show

Most of the "GLP-1 and cancer" headlines so far have been about solid tumours, the kind that grow in the breast, bowel or pancreas. A large 2026 study is the first to look hard at blood cancers instead, in more than 405,000 people with type 2 diabetes. It found something worth understanding carefully, because the honest version is narrower and more interesting than "Ozempic prevents blood cancer."

Quick answer: do GLP-1 drugs lower blood cancer risk?

In the largest analysis to date, GLP-1 medications were linked to a 36% lower risk of one blood cancer, multiple myeloma (hazard ratio 0.64), but showed no clear effect on the other main blood cancers such as acute leukaemia (Irons and colleagues, eClinicalMedicine, 2026). So the accurate takeaway is not that GLP-1 drugs lower blood cancer risk across the board. The signal points to a single disease, it comes from observational data, and it is an association, not proof that the drugs prevent anything.

What the 405,000-patient study actually found

Researchers used the TriNetX network, a database drawing on 91 healthcare organisations, to follow 405,454 adults with type 2 diabetes between 2019 and 2024. They compared 50,152 people taking a GLP-1 medication such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) against people on a different diabetes drug class or on neither. Then they tracked who went on to develop a blood cancer.

Each figure below compares GLP-1 users with the comparison group. A hazard ratio under 1.00 means lower risk, and the range in brackets is the 95% confidence interval, the band the true effect most likely sits within. When that band crosses 1.00, the result is not statistically significant.

Blood cancer	Hazard ratio (95% CI)	Plain meaning
Multiple myeloma	0.64 (0.45 to 0.90)	36% lower risk, significant
Acute myeloid leukaemia	0.81 (0.52 to 1.27)	No significant difference
Chronic myeloid leukaemia	1.06 (0.58 to 1.92)	No significant difference
Myelodysplastic syndrome	0.98 (0.68 to 1.40)	No significant difference

The myeloma result was the only one that reached significance, and it grew stronger in people whose diabetes was poorly controlled, with an HbA1c above 8% (hazard ratio 0.33, 0.12 to 0.90). Multiple myeloma is a cancer of plasma cells in the bone marrow, and obesity and type 2 diabetes are among its known risk factors, which is part of why researchers looked here in the first place.

Why "blood cancer" is the wrong headline

Blood cancer is not one disease. It is a family of very different conditions, and this study found a benefit signal for exactly one of them. Acute myeloid leukaemia, chronic myeloid leukaemia and myelodysplastic syndrome all came back with confidence intervals that crossed 1.00, meaning the data could not distinguish their result from no effect at all. Reading "GLP-1 drugs cut blood cancer risk" from this study would stretch a single, specific finding across a whole category it does not cover.

This matters for a practical reason. If you or a family member is watching one of the other blood cancers, this study offers no evidence that a GLP-1 medication changes that risk in either direction. The reassuring number belongs to myeloma alone, and even there it is a starting point rather than a settled fact.

It also echoes a pattern we have seen across the wider cancer research. In our look at whether GLP-1 drugs lower cancer risk in a 64,000-patient study, the class was tied to lower rates of several obesity-linked solid tumours, but the effect was uneven and vanished for some cancers once the analysis accounted for early detection. The story keeps rhyming: real signals for specific cancers, no blanket protection.

The scarier number in the study is about survival, not risk

The same paper looked at a second, separate question: among people with type 2 diabetes who already had a blood cancer, did their diabetes medication track with how long they lived? Here the finding involved a different drug class. People taking SGLT2 inhibitors, a common diabetes and heart-failure medicine, had a higher risk of dying if they had multiple myeloma (hazard ratio 2.27), acute myeloid leukaemia (2.00) or chronic myeloid leukaemia (2.68).

Two cautions keep this in perspective. First, this is a mortality signal in people who were already diagnosed, which is a completely different thing from causing or preventing the cancer. Second, the analysis could not separate deaths caused by the cancer from deaths from other causes, so it cannot say the SGLT2 drugs were to blame. It is a flag for more research, not a reason to change a prescription. The one clean message is that GLP-1 medications and SGLT2 inhibitors behaved differently in this data, and that difference is worth studying rather than assuming.

What this does and does not prove

This was an observational study, which means nobody was randomly assigned to a GLP-1 drug. The people who received one were younger on average, more likely to be female and had a higher body mass index than those who did not. Statistical adjustment can narrow gaps like these, but it cannot fully remove them, so some of the myeloma difference could reflect who gets prescribed these drugs rather than the drugs themselves. Researchers call this confounding by indication, and it is the built-in limit of this kind of study.

The authors are candid about several other limits. Coded medical records cannot confirm whether prescriptions were actually filled or taken. Details about each cancer's genetics, risk stratification and treatment were not available. The group was mostly White, which leaves less certainty for other populations. And the chronic myeloid leukaemia analysis in particular rested on very few cases, so a handful of events could have flipped the result.

One encouraging thread does sit alongside this study. A separate analysis of 1,097 veterans with diabetes and monoclonal gammopathy of undetermined significance, a benign condition that can precede myeloma, found that those exposed to GLP-1 medications had a lower risk of progressing to full multiple myeloma (hazard ratio 0.45). Two datasets pointing the same way is more persuasive than one, but early findings like these still need trials designed to test the question directly before anyone can call it cause and effect.

What this means if you take a GLP-1

If you are on Ozempic, Wegovy, Mounjaro or another GLP-1 for diabetes or weight, this is a piece of cautious good news, not a reason to start or stay on the medication for cancer protection. No GLP-1 drug is approved to prevent any cancer, the myeloma finding is preliminary, and it may partly reflect the metabolic benefits of losing weight and getting blood sugar under control rather than a direct effect on cancer cells.

That framing is where the practical steps live. The leading explanation for signals like this is that GLP-1 medications lower the chronic inflammation and metabolic stress that come with obesity and diabetes, and that is worth supporting through the whole picture of how you eat and live, not through any single product.

1. Keep your routine cancer screening and blood work on schedule. A GLP-1 medication does not replace any of it.
2. Treat the diabetes and weight goals as the main event. The metabolic improvements are what the strongest theories credit, and they are real and measurable.
3. Watch your nutrition while your appetite is suppressed, because eating far less is easy to do and easy to underestimate.
4. Do not start, stop or change a prescription based on a single observational study. Talk it through with your prescriber.

Protecting your nutrition while you eat less

GLP-1 medications work by quietening appetite, which quietly shrinks how much food you take in. Over months that can leave you short on the vitamins and minerals your body still needs, including vitamin B12, vitamin D, magnesium and iron. It can also cost you muscle if protein drops too low, which is why our guide to muscle loss and protein intake is worth a read alongside this one. Managing the more common GLP-1 side effects, from nausea to constipation, gets easier when your nutrient status is solid rather than slipping.

Closing that gap is where a considered plan helps. The GLP-1 supplement protocol walks through what to take and how much, and GLP-1 Shield is built around the nutrients people most often run low on while losing weight. To be clear, no supplement prevents or treats cancer of any kind, and anyone claiming one does is overselling. The point is to support your overall health while your medication does its job.

Key takeaways

• A 2026 study of 405,454 adults with type 2 diabetes tied GLP-1 medications to a 36% lower risk of multiple myeloma (hazard ratio 0.64).
• The benefit was specific to myeloma. Acute leukaemia, chronic myeloid leukaemia and myelodysplastic syndrome showed no significant difference.
• The study also found higher death rates in blood-cancer patients taking SGLT2 inhibitors, a separate drug class and a survival question, not a risk one.
• This is observational data. It shows an association, not proof that GLP-1 drugs prevent multiple myeloma.
• No GLP-1 medication or supplement is approved to prevent cancer. Keep screening, blood work and nutrition on track.

Evidence current as of August 24, 2026. This article is general information, not medical advice. GLP-1 medications are prescription-only and should be used under medical supervision. If you have a personal or family history of blood cancer, discuss it with your doctor rather than acting on a single study.

Frequently asked questions

Can Ozempic or Wegovy lower your risk of blood cancer?

The evidence points to one blood cancer only. A 2026 study of 405,454 adults with type 2 diabetes found GLP-1 medications were tied to a 36% lower risk of multiple myeloma (hazard ratio 0.64), but no significant change for acute leukaemia, chronic myeloid leukaemia or myelodysplastic syndrome. It is observational data, so it shows an association, not proof that GLP-1 drugs prevent myeloma.

Why would a diabetes drug affect multiple myeloma at all?

Obesity and type 2 diabetes are known risk factors for multiple myeloma, and the leading theory is that GLP-1 medications reduce the chronic inflammation and metabolic stress that come with them. Whether the effect is direct or simply a by-product of weight loss and better blood sugar is still unknown, and only a trial designed to test it can answer that.

Does this mean GLP-1 drugs protect against leukaemia too?

No. In this study, acute myeloid leukaemia (hazard ratio 0.81), chronic myeloid leukaemia (1.06) and myelodysplastic syndrome (0.98) all had confidence intervals that crossed 1.00, meaning no significant effect was found in either direction. The reassuring number applies to multiple myeloma alone, not to blood cancers as a group.

Should I take a GLP-1 medication to prevent cancer?

No GLP-1 drug is approved to prevent any cancer, and this early observational finding is not a reason to start or continue one for that purpose. GLP-1 medications are prescribed for type 2 diabetes and weight management. Any decision about starting, stopping or switching should be made with your prescriber, based on your own health and risks.